Alternatively, latency II, in which the immunodominant EBNA3 gene family is not expressed, could represent the requirement to minimise the recognition of tumour cells by the immune system in immunocompetent individuals while still retaining critical virally-mediated oncogenic activities such as NF-κB signalling promoted by EBV’s oncogene, LMP1 [83,84]. This evidence concerns the gene PDLIM7 and neoplasm.